Compare General Mills, Inc. (GIS) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Mills, Inc. vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? General Mills, Inc. trades at $32.31 (market cap $17.02B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: General Mills, Inc. is far larger — about 17.5× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and General Mills, Inc. pays a 7.67% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold General Mills, Inc. for 107 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| GIS | MRVI | |
|---|---|---|
Market Cap | $17.02B | $972.90M |
Volume | 7,979,067 | 4,325,710 |
Sector | Consumer Staples | Health |
52-Week High | $49.18 | $9.00 |
52-Week Low | $31.67 | $2.83 |
Typical Hold Time | 107 Days | 0 Days |
Enterprise Value | $30.20B | $1.08B |
Dividend Yield | 7.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Mills (GIS) trades at $31.83, down 2.66% amid bearish technical signals and negative profitability metrics. The stock shows mixed earnings performance with a recent Q2 beat but Q4 miss, while revenue has declined from $20.1B in 2023 to $19.5B in 2025. Analyst consensus remains cautious with 61% hold ratings, though the $36 price target suggests 13% upside potential. Recent CEO transition and dividend declaration provide stability signals despite profitability challenges.
The outlook remains challenged by declining margins and negative ROE/ROA, though attractive valuation (P/E 9.2) and dividend yield offer value appeal. Key risks include continued revenue pressure, margin compression, and high debt levels at 45% of assets. Upside depends on successful execution of the $3B savings plan and international growth initiatives.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
